Towards a virtual biopsy: an improved multimodal imaging biomarker to guide treatment decisions in neuro-oncology by combining advanced tissue microstructure imaging with deep learning
Ended Project Grant Awarded Last action
- Award ID
- R44NS120796
- Recipient
-
Cortechs Labs, Inc. UEI Y5NZZ4QS5G23
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $764,055
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Originally
- Funding
-
- $509,370.00 Federal
- $254,685.00 Non-federal
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis for neuro- oncology patients remains poor, with a mean survival of 12-15 months for high-grade gliomas. One major reason for poor survival is that IT remains difficult to accurately assess tumor progression and treatment-related changes on standard imaging. This limits necessary information for guiding biopsies or resecting malignant tissue. In addition, new therapies can cause radiological patterns that obfuscate the underlying course of the disease. As a result, there is a critical need for new quantitative imaging tools to evaluate brain tumors and their progression. The goal of this proposal is to develop novel quantitative imaging biomarkers using the combination of advanced tissue microstructure imaging and deep learning to accurately discriminate tumor from non-tumor tissue, measure tumor progression and treatment response, and predict clinical outcomes. This approach utilizes restricted spectrum imaging (RSI), an advanced diffusion-weighted imaging technique that models the restricted diffusion of water to improve tumor conspicuity. Phase I of this proposal will develop a hybrid multimodal, RSI-based biomarker for brain cancer, quantify the biomarker in abnormal sub-regions, and demonstrate the biomarker's performance in predicting clinical outcomes. Phase II of this proposal will develop and deploy commercial-grade software to the cortechs labs cloud platform, demonstrate its clinical usability and utility, and generate the materials required for a 510K FDA submission. The AI technology developed through this proposal will ultimately serve as a clinical decision support tool to improve clinician performance in diagnosing and evaluating brain tumors and predicting tumor response to treatment.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $254,685 | $0 | |
| Original award | $254,685 | $254,685 |
Quick answers
Who received award R44NS120796?
R44NS120796 was awarded to Cortechs Labs, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 22, 2021.
How much is award R44NS120796 worth?
$764,055 has been obligated on R44NS120796: $509,370 in federal funding and $254,685 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award